Medical Professionals: Physician Briefing: Development

Development of the AdvantaJet® Needle-Free Injection System   Development of the AdvantaJet® needle-free injection system is the latest advancement in jet injection technology. In 1986, jet injection technology began to focus on home care diabetic use. The first few devices were large and awkward to handle. Over the years, design improvements were implemented. Interest in jet injection methodology heightened as studies indicated that the rate of subcutaneous insulin absorption increased as the surface to which the insulin was exposed increased. Further studies determined that the subcutaneous administration of insulin as a jet spray, similar to that used for mass inoculations in the military, resulted in a more rapid increase in plasma insulin concentration. The AdvantaJet® Injector was developed over a six-year period in a public and private industry collaboration with medical professionals. Initial clinical testing was conducted at Sacre Coeur Hospital in Montreal during 1984 under a protocol coordinated with Health and Welfare Canada. Regulatory work with the U.S. Food and Drug Administration was completed in the summer of 1985. The AdvantaJet® injector was categorized as a Class II medical device. AdvantaJet® Systems incorporate a total support system, including comprehensive training, extraordinary service and 24-hour helpline. The injection system also comes with an easy-to-follow instruction manual, a warranty that provides an exchange if necessary, and companion demonstration video. Plus, there is a 24-hour toll-free helpline should your patient have any questions or concerns.